文献速递胸部肿瘤

中央型早期非小细胞肺癌立体定向体部放疗:前瞻性I/II期试验结果

Stereotactic Body Radiation Therapy for Central Early-Stage NSCLC: Results of a Prospective Phase I/II Trial.
PubMed 文献 · J Thorac Oncol · 2018-07-26

该前瞻性I/II期试验评估中央型早期非小细胞肺癌患者接受立体定向体部放疗的耐受性和疗效。I期确定II期剂量为11 Gy×5次,II期2年局部控制率85%,但部分患者出现严重晚期毒性。

要点

  • II期推荐剂量为11 Gy×5次,2年局部控制率85%。
  • 2年总生存率43%,急性3-4级心肺毒性发生率6%。
  • 可评估晚期毒性患者中27%出现3级、12%出现4级、4%出现5级毒性。

核心结论

  • 中央型早期NSCLC采用11 Gy×5次立体定向体部放疗耐受性可,局部控制率优秀,但部分患者出现严重晚期毒性。

研究设计与样本

  • I期采用5次分割,剂量递增为9、10、11、12 Gy/次;II期主要目标为确定I期最大耐受剂量能否使2年局部控制率超过80%。

主要发现

  • I期2例接受10 Gy×5次患者出现无关的急性3级肺毒性并缓解,II期选择剂量为11 Gy×5次。
  • II期存活患者中位随访27个月(范围9-58个月),11 Gy×5次组2年局部控制率85%(95%CI 62%-95%),2年总生存率43%(95%CI 28%-57%)。
  • 3例(6%,95%CI 1%-17%)出现急性3级和4级心脏或肺毒性。
  • 41例可评估晚期心肺毒性患者中,11例(27%,95%CI 14%-43%)出现3级毒性,5例(12%,95%CI 4%-26%)出现4级毒性,1例(4%,95%CI 0%-13%)死于5级毒性。

关键数值与推荐

  • II期推荐剂量为11 Gy×5次。
  • 2年局部控制率85%(95%CI 62%-95%),2年总生存率43%(95%CI 28%-57%)。
  • 急性3-4级心肺毒性发生率6%(95%CI 1%-17%)。
  • 晚期3级毒性27%(95%CI 14%-43%),4级12%(95%CI 4%-26%),5级4%(95%CI 0%-13%)。

临床怎么用

  • 对于医学上不可手术的中央型早期NSCLC,可考虑11 Gy×5次立体定向体部放疗,但需密切监测晚期心肺毒性。

局限性

  • 样本量较小,随访时间有限,晚期毒性评估仅41例可评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We report results from a prospective phase I/II trial for patients with centrally located, early-stage NSCLC receiving stereotactic body radiation therapy. METHODS: Eligible patients were medically inoperable with biopsy-proven NSCLC within 2 cm of the proximal bronchial tree or 5 mm of the mediastinal pleura or parietal pericardium. Phase I had four dose levels using 5 fractions: 9, 10, 11, and 12 Gy per fraction. The primary phase II objective was to determine if the maximum tolerated dose in phase I achieved local control greater than 80% at 2 years. RESULTS: Seventy-four patients were enrolled; 23 to phase I and 51 to phase II. Two phase I patients treated with 10 Gy × 5 fractions developed unrelated acute grade 3 lung toxicities which resolved. The phase II dose level selected was 11 Gy × 5 fractions. The median follow-up for living phase II patients was 27 months (range, 9 to 58 months). Two-year local control using 11 Gy × 5 fractions was 85% (95% confidence interval [CI]: 62%-95%). Two-year overall survival was 43% (95% CI: 28%-57%). Three patients (6%, 95% CI: 1%-17%) experienced acute grade 3 and 4 cardiac or pulmonary toxicities. Of the 41 patients evaluable for late cardiac and pulmonary toxicity, 11 (27%, 95% CI: 14%-43%) developed grade 3, 5 (12%, 95% CI: 4%-26%) developed grade 4, and 1 (4%, 95% CI: 0%-13%) died of grade 5 toxicity. CONCLUSION: Stereotactic body radiation therapy for central NSCLC using 11 Gy × 5 fractions is tolerable and has excellent local control, but is associated severe late toxicity in some patients.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Roach MC, Robinson CG, DeWees TA, et al. Stereotactic Body Radiation Therapy for Central Early-Stage NSCLC: Results of a Prospective Phase I/II Trial. J Thorac Oncol. 2018. PMID: 30056162. doi:10.1016/j.jtho.2018.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。